WO2014197137A1 - Formulation résistante à un usage détourné - Google Patents

Formulation résistante à un usage détourné Download PDF

Info

Publication number
WO2014197137A1
WO2014197137A1 PCT/US2014/035768 US2014035768W WO2014197137A1 WO 2014197137 A1 WO2014197137 A1 WO 2014197137A1 US 2014035768 W US2014035768 W US 2014035768W WO 2014197137 A1 WO2014197137 A1 WO 2014197137A1
Authority
WO
WIPO (PCT)
Prior art keywords
diversion
formulation
human
resistant
ingredient
Prior art date
Application number
PCT/US2014/035768
Other languages
English (en)
Inventor
Howard Brooks-Korn
David Alan LOWIN
Original Assignee
Howard Brooks-Korn
Lowin David Alan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Howard Brooks-Korn, Lowin David Alan filed Critical Howard Brooks-Korn
Publication of WO2014197137A1 publication Critical patent/WO2014197137A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • This invention relates to formulations for the treatment of animals by the administration of an active agent that has the potential for diversion and abuse by humans.
  • U.S. Patent No. 8,410, 129 discloses the use of opiates for treatment of centrally and peripherally mediated neuropathies, polyneuropathies, disorders and syndromes including but not limited to lingual, pharyngeal, laryngeal, esophageal, urinary bladder sphincter, lumbar and lumbo-sacral spine, pelvis and pelvic-limb paresis/paralysis.
  • This patent reports the successful reversal of paresis/paralysis in such disorders and syndromes, particularly by administering immediate or sustained release pharmaceutical formulations of hydrocodone, oxycodone and morphine sulfate, and teaches the similar use of other opioids.
  • Particularly preferred among the opioids employed in the ⁇ 29 patent is oxycodone sustained release (OxyContin®) provided in the original formulation, e.g., as taught in U.S. Patent No. 5,508,042, which expired on April 16, 2013.
  • auxiliary substance selected from (a)-(f): (a) a substance that irritates the nasal passages and/or pharynx, (b) a viscosity-increasing agent, which, with the assistance of a necessary minimum quantity of an aqueous liquid, forms a gel with the extract obtained from the dosage form, which gel preferably remains visually distinguishable when introduced into a further quantity of an aqueous liquid, (c) an antagonist for each of the active ingredients with abuse potential, (d) an emetic, (e) a dye, or (f) a bitter substance.
  • auxiliary substance selected from (a)-(f): (a) a substance that irritates the nasal passages and/or pharynx, (b) a viscosity-increasing agent, which, with the assistance of a necessary minimum quantity of an aqueous liquid, forms a gel with the extract obtained from the dosage form, which gel preferably remains visually distinguishable when introduced into a further quantity of an
  • auxiliary substance(s) are taught to be present in a spatially separated arrangement from the other components of the dosage form, such that their effect would only manifest upon attempts to abuse the formulations, for example by breaking, cutting, crushing or dissolving.
  • the '383 patent teaches the use of one or more constituents of radix ipecacuanha (ipecac root), preferably based on the constituent emetine.
  • Auxiliary substances (c) and/or (d) and/or (f) are taught to be present in such a low dose that, when correctly administered, the dosage form is able to bring about virtually no effect which impairs the patient or the efficacy of the active ingredient.
  • Emetine is taught to be present preferably in a quantity > 10 mg, particularly preferably > 20 mg, and very particularly preferably > 40 mg per dosage form.
  • the detractant could be considered a contaminant if included in a formulation intended for human consumption (e.g., hair, sand, insect parts or feces, treated to be non-harmful for a subject of the species for which the formulation is intended), but while feasible, the use of such detractants presents additional challenges to providing a veterinary product.
  • a formulation intended for human consumption e.g., hair, sand, insect parts or feces, treated to be non-harmful for a subject of the species for which the formulation is intended
  • the use of such detractants presents additional challenges to providing a veterinary product.
  • such veterinary formulations can be manufactured in a dosage form that is unsuitable for human consumption, e.g., a chew bone.
  • Such veterinary products can be prominently labeled to highlight the presence of the detractant as a warning against human consumption.
  • a diversion-resistant veterinary formulation which includes an active agent that has the potential for diversion and abuse by humans, and an anti-diversive ingredient that is acceptable to a non-human animal for which the formulation is intended and unacceptable to a human being, where the anti-diversive ingredient is:
  • the anti-diversive ingredient causes an adverse reaction in the human but not in the animal for which the formulation is intended.
  • adverse reactions include, without limitation, nausea, emesis, pain, fever, puritis, rash, diarrhea and the like.
  • One preferred group of nausea and/or emesis-causing anti-diversive ingredients includes ipecacuanha (ipecac or one of its active components, emetine and cephaeline), CCK8 and copper sulphate, particularly where the animal for which the formulation is intended is a dog.
  • Active agents having the potential for diversion and abuse by humans include, without limitation, depressants, opioids and morphine derivatives, stimulants, and dextromethorphan.
  • One particularly advantageous use of these formulations is for opiates, particularly oxycodone.
  • Human effective amounts of ipecac can be in the range of about 0.001 mg/kg to about 0.1 mg/kg, or about 0.005 mg/kg to about 0.05 mg/kg.
  • a veterinary formulation made to resist diversion assuming an average 70 kg human can include from about 0.07 mg to about 7.0 mg of ipecac.
  • An alternative, more narrow human effective range is from about 0.35 mg to about 3.5 mg of ipecac.
  • Formulations employing only emetine or cephaeline will use slightly lower effective amounts.
  • a diversion-resistant canine veterinary formulation including: an active agent that has the potential for diversion and abuse by humans, and an anti- diversive ingredient to which humans are more sensitive than are dogs, the anti-diversive ingredient being present in a human effective amount and less than an animal effective amount and selected from the group: ipecac, emetine, cephaeline, CCK8 and copper sulphate.
  • Such a formulation can be further formulated to release said anti-diversive agent at a pH characteristic of a quiescent human stomach, but lower than a mean of the pH of a quiescent canine stomach.
  • Another diversion-resistant canine veterinary formulation includes: an active agent that has the potential for diversion and abuse by humans, and ipecac in an amount sufficient to cause nausea and/or emesis in a human but insufficient to cause nausea and/or emesis in a dog.
  • the diversion-resistant canine veterinary formulation can include from about 0.07 mg to about 7.0 mg of ipecac, preferably formulated for immediate release.
  • the active agent that has the potential for diversion and abuse by humans is oxycodone
  • the formulation can include from about 10 mg to about 40 mg of oxycodone, preferably formulated for sustained release.
  • the ipecac in such formulations can be formulated for release below a pH in the range of about 1 .6 to 2.0, or preferably to prevent release above about pH 1 .7.
  • an opioid compound encompasses one or more opioids, as well as mixtures thereof.
  • Carriers or “vehicles” as used herein refer to pharmaceutically and/or veterinarily accepted excipients known to be suitable for use in drug formulation and administration. Carriers and vehicles useful herein include, but are not limited to any such material known in the art, which is nontoxic and does not interact with other components of the composition in a deleterious manner.
  • Extended release or “sustained release” is defined for purposes of the present invention as the rate at which a drug must be released after administration in order to maintain a therapeutically effective blood (plasma) level for a minimum of about 6 hours, but preferably lasting 12 to 36 hours or longer. This term is also employed to identify a formulation having such a release profile.
  • immediate release is defined for purposes of the present invention as the rate at which a drug must be released after administration in order to maintain a therapeutically effective blood (plasma) level for period of about 6 hours or less. This term is also employed to identify a formulation having such a release profile.
  • non-human animal for which the formulations of the present invention are intended include but are not limited to, mice, rats, ferrets, simians, farm animals, sport animals, and pets such as dogs and cats.
  • human effective amount is meant an amount of an anti-diversive ingredient in a quantity sufficient to provide a desired effect, e.g., causing nausea and/or emesis, in a human.
  • animal effective amount is meant an amount of an anti-diversive ingredient in a quantity sufficient to provide an undesired effect, e.g., causing nausea and/or emesis, in a non-human animal for which the formulation is intended.
  • terapéuticaally effective amount is meant a nontoxic amount of a drug, active agent or formulation in a quantity sufficient to provide a desired therapeutic effect, e.g., treatment of an ailment.
  • Active agents having a potential for diversion and abuse by humans include, without limitation, depressants, opioids and morphine derivatives, stimulants (e.g., amphetamine/dextroamphetamine, dextroamphetamine and methylphenidate), and dextromethorphan.
  • the active agent is an opiate, especially oxycodone (sustained or immediate release).
  • Examples of opiates that can be used in the present invention include, but are not limited to: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, beta- hydroxy 3-methylfentanyl, bezitramide, buprenorphine, butorphanol, carfentanil, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diacetylmorphine (heroin), diampromide, dihydrocodeine, dihydroetorphine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine
  • Active agents having the potential for diversion and abuse by humans can typically be administered by any suitable route.
  • the present invention is predominantly concerned with oral administration and preventing the diversion of such veterinary products for use by humans whether orally or by crushing to circumvent sustained release, for inhalation, or for injection.
  • the present invention provides veterinary formulations including a therapeutically effective amount of an active agent, an effective amount of an anti-diversive ingredient, and optionally a carrier.
  • the formulations can include a mixture of two or more active agents and can be for immediate or sustained release.
  • the formulation can include adjuvants, diluents, buffers, other detractants and the like. Actual methods of preparing such dosage forms are well known or will be apparent to those skilled in the art. For example, see: Remington: The Science and Practice of Pharmacy, Nineteenth Ed. (Easton, Pa.: Mack Publishing Company, 1995).
  • the anti-diversive ingredient preferably causes an adverse reaction in the human, but not in the animal for which the formulation is intended.
  • adverse reactions include, without limitation, nausea, emesis, pain, fever, puritis, rash, diarrhea and the like.
  • Nausea and/or emesis-causing anti-diversive ingredients include, without limitation, apomorphine, 1 ,2-dihydroxyaporphine, cisplatin, cholecystokinin octapeptide (CCK8), copper sulphate, cyclophosphamide, ipecacuanha (ipecac or either of it's active components, emetine and cephaeline), lithium chloride, morphine, nicotine, and rolipram.
  • a preferred group of nausea and/or emesis-causing anti-diversive ingredients includes ipecacuanha (or emetine or cephaeline), CCK8 and copper sulphate.
  • the anti-diversive ingredients of the present invention can be broadly characterized as suitable or acceptable to a non-human animal (for example, to dogs) but unsuitable or unacceptable to human beings. They can, however, be distinguished as an improvement over the detractants described in U.S. Applications Serial Nos. 1 1/395,200 and 1 1/395,242, in that such detractants were focused upon differential sensitivities between species (dogs and cats generally being attracted by a variety of strong odors, flavors and/or textures that are generally unpalatable to human beings) and upon human emotional reactions to detractants that could otherwise be viewed as contaminants in a formulation intended for humans, such as hair, sand, insect parts or even feces.
  • One approach to providing an effective anti-diversive ingredient is to select an ingredient that is active in humans but not active in the non-human animal for which the formulation is intended.
  • a second approach to providing an effective anti-diversive ingredient is to select an ingredient to which humans are more sensitive than the non- human animal for which the formulation is intended.
  • a third approach to providing an effective anti-diversive ingredient is to formulate such an ingredient to remain biologically unavailable in the non-human animal for which the formulation is intended, but bioavailable when administered to a human. Combinations of these approaches can also be advantageously employed.
  • Ipecac has long been known as an emetic. It is prepared from the dried rhizome and roots of the Cephalis acuminate or C. ipecacuanha plant. Its principal active ingredients are the ether-soluble alkaloids emetine and cephaeline (present in a ratio of approximately 0.8:1 .0, but, this ratio varies depending upon product and method of manufacture). It has most commonly been provided in the form of a syrup containing not less than 1.23 mg per ml. or more than 1.57 mg per ml. of the ether-soluble alkaloids in glycerin and can contain between 1.0% and 2.5% ethanol (USP). Typical emetic doses are 5 ml. - 10 ml. (children 6 to 12 months), 15 ml. (children 1 -12 years) and 15 - 30 ml_ (adolescents and adults); administration is typically preceded or followed by water.
  • Emetine used for over 100 years as a treatment for dysentery, can irritate skin if applied topically; it is a cardiotoxin and has been associated with serious cardiotoxicity (see, www.drugs.com/npp/ipecac.html).
  • the 0.5 mL/kg dosage corresponds to an animal effective amount in the range of 0.615 mg/kg to 0.785 mg/kg, or about 0.7 mg/kg (based on the 1.23 to 1 .57 mg per mL concentration specifications for syrup of ipecac).
  • a formulation containing 7 mg of ipecac would be expected to cause nausea and/or emesis in a 10 kg dog; 14 mg of ipecac for a 20 kg dog and 28 mg for a 40 kg dog.
  • These dosages are consistent with the absence of nausea and/or emesis with the significantly lower dosages employed in the formulations of the present invention.
  • the response to ipecac is "very intense in humans but only weak in dogs" (Predicting the emetic liability of novel chemical entities: a comparative study, du Sert, et al., Br J Pharmacol, 2012 March; 165(6): 1848-1867.)
  • the study reported by du Sert, et al. entailed a systematic review of publications identified from PubMed reporting experimental data on the use of ten emetic compounds, with the objective of comparing emetic compounds across species to investigate whether dogs, ferrets and rats are similarly predictive of humans.
  • the ten emetic compounds are apomorphine, cisplatin, cholecystokinin octapeptide (CCK8), copper sulphate, cyclophosphamide, ipecacuanha, lithium chloride, morphine, nicotine, and rolipram.
  • a formulation containing a human effective amount of ipecac (or one of its ether-soluble alkaloids emetine and cephaeline), i.e., an amount effective to induce nausea and/or vomiting in the human can contain significantly less than an animal effective amount of ipecac, i.e., an amount effective to induce nausea and/or vomiting in the dog.
  • a human effective amount of ipecac can, e.g., be in the range from about 0.001 mg/kg to about 0.1 mg/kg, or about 0.005 mg/kg to about 0.05 mg/kg. At the upper limits, 20 mg/kg has been reported to constitute a toxic dose of emetine.
  • anti-diversive ingredients in the present invention do not require causing an emetic response equal in intensity with that caused by cisplatin treatment.
  • the anti-diversive effect need only cause sufficient discomfort to cause a human to avoid taking the diversion-resistant formulation (preferably via any route of administration); in that regard, substantially lower and safer amounts of anti-diversive ingredient can be employed.
  • a human effective amount of ipecac that is less than an animal (i.e., canine) effective amount can be about 0.07 mg to about 7.0 mg, preferably about 0.35 mg to about 3.5 mg, or more specificaly about 0.5 mg to about 1 .5 mg, or even more specifically about 0.5 mg to about 1 .0 mg, or generally about 1 .0 mg for a typical 70 kg human.
  • the human effective amount and animal effective amount of anti-diversive ingredient may vary as a function of the particular ingredients used and of the formulation or the dosage form.
  • the optimum formulation and effective amounts for a particular dosage form can be determined by simple preliminary testing.
  • an active agent having a potential for diversion and abuse by humans is formed into particles with a pH dependent binder, having substantially smooth, non-rugose surfaces which are coated with a coating material, preferably a coating material which is poorly soluble at about pH 4.5 and below, but readily soluble at, about pH of 5.5 and above.
  • anti-diversive ingredient can be similarly bound, coated and formed into particles.
  • an effective amount can be formed into immediate release particles by selection of pH independent binders and coatings.
  • Anti-diversive ingredients desired to remain biologically unavailable in the non- human animal for which the formulation is intended, but bioavailable when administered to a human can be formed into particles, for example, employing a pH dependent coating that is insoluble in the animal but soluble in the human.
  • a pH dependent coating that is insoluble in the animal but soluble in the human.
  • the anti-diversive ingredient of the present invention can be formulated to prevent release above a pH range of about 1 .6 to 2.0, preferably preventing release above about pH 1 .7 to facilitate making the anti-diversive ingredient available to the human but not the dog.
  • Examples of formulations designed to effect release at specific pHs can be found in the literature, e.g., Balamuralidhara, et al., pH Sensitive Drug Delivery Systems: A Review, Am. J. Drug Discovery and Devel. 1 (1 ): 24-48, 201 1.
  • the effective pH ranges can be confirmed for other breeds and/or species by measuring pH in the quiescent stomach. Utility of the species selectiveness of the present formulations can be directly tested in vivo.
  • the diversion resistant formulation addressed to both differences in species sensitivity to the anti-diversive ingredient and differences in gastrointestinal pH.
  • the diversion resistant formulation will contain an anti- diversive ingredient in a human effective amount that is less than an animal effective amount, protectively treated to release at the lower pH of a quiescent human stomach but not in the slightly higher pH of a quiescent canine stomach.
  • One such preferred diversion resistant formulation contains an effective amount of oxycodone hydrochloride (e.g., 20 mg or 40 mg) formulated for sustained release, and a human effective amoiunt of ipecac (e.g., 0.35 mg to about 3.5 mg, or more specificaly about 0.5 mg to about 1 .5 mg, or about 1.0 mg.) formulated for immediate release at a pH characteristic of a quiescent human stomach, but lower than a mean pH of a quiescent canine stomach, e.g., below about pH 1.6 to 2.0, preferably preventing release above a pH of about 1 .7, and a veterinarily accepted carrier.
  • an effective amount of oxycodone hydrochloride e.g., 20 mg or 40 mg
  • a human effective amoiunt of ipecac e.g., 0.35 mg to about 3.5 mg, or more specificaly about 0.5 mg to about 1 .5 mg, or about 1.0 mg.
  • the active agent and anti-diversive ingredient are preferably indistinguishable in order to prevent sorting to eliminate the anti-diversive ingredient for abuse.
  • the formulations can include additional ingredients, veterinarily acceptable carriers, processing and/or packaging to render them tamper-resistant, to dissuade extraction and separation of the active agent(s) and thereby dissuade diversion or abuse.
  • such formulations can include excipients that maintain the effectiveness of the active agent, such that its extraction and/or separation of the active agent from one or more such ingredients of the formulation would render the agent unpalatable, less active or completely inactive.
  • Detractants can be added to these formulations to render them unsuitable for use by other than the intended route of administration, e.g., adding capsaicin to a tablet in an amount that would not interfere with normal swallowing and absorption, but would dissuade misuse by snorting or dissolving the tablet for injection.
  • the amount of active agent administered will be dependent on the particular drug selected, the age and general condition of the subject being treated, the severity of the subject's condition, the dosing regimen and the judgment of the prescribing veterinarian. While daily dosing regimens can involve the administration of as many as eight doses, it is generally preferred that the number of doses be kept to a minimum for example to facilitate patient compliance. Moreover, the longer acting sustained-release dosage forms maintain a more consistent plasma concentration of the active agent, avoiding peaks and troughs.
  • the lowest therapeutically effective dosage is the least amount of the pharmaceutical formulation sufficient to effect treatment.
  • opioids administered for treating pain or paresis/paralysis specifically oxycodone
  • a starting dose of oxycodone sustained release can be about 10 mg to about 20 mg given every 12 hours.
  • the dose of medication is adjusted according to the weight and need of a subject, to ameliorate the presenting symptoms.
  • One of ordinary skill in the art will have the experience and means to determine the adjustment needed.
  • the dose is elevated by a factor ranging from 1.25 to 2.0 times the original dosage (preferably 1 .5 times the original dose, e.g., 10 mg twice daily is increased to 15 mg twice daily) escalating on about a weekly basis until the symptoms are effectively treated at a well-tolerated dosage.
  • the dose can be increased in 10 mg increments.
  • the maximum dose of oxycodone sustained release administered to dogs has been 40 mg twice daily.
  • the highest tolerated dosage is the maximum amount of the pharmaceutical formulation to effect treatment without the occurrence of adverse side effect(s) outweighing the benefit received. If the subject's highest tolerated dosage is reached, treatment should be discontinued, optionally re-commencing treatment by substituting a different active agent or formulation.
  • the dose employed for the anti-diversive ingredient of the invention will preferably be the lowest human effective dose shown to work in a statistically significant portion of human volunteers tested with a given formulation, and in any case lower than the animal effective dose.
  • an effective dose can be as much as about 0.1 mg/kg; effective doses can be as low as about 0.01 mg/kg or even 0.001 mg/kg.
  • Clinical assessments of nausea can be performed by counting emetic events (vomiting or retching) and by observation of increased salivation, lip licking, frequent and/or exaggerated sallowing motions, lethargy, restlessness and/or panting. The observations are quantified using a Visual Analog Scale (VAS). Degree of nausea is quantified by drawing a single vertical line to intersect a 100 millimeter horizontal line. The distance in millimeters from this intersection to the left origin of the VAS represents the severity of nausea. A score of zero is defined as no nausea and a score of 100 is defined as the worst possible nausea. (See, NADA 141-262.)
  • the formulation or a control having no anti-diversive ingredient is administered to a group of test animals and to a group of human volunteer test subjects sufficiently large to provide reliable (e.g., statistically significant) results confirming that the amount of anti-diversive ingredient causes the intended response in humans but not in animals in the particular formulation.
  • the evaluation can be initially conducted using formulations without any active agent, so the effectiveness of the amount of anti-diversive ingredient can be determined without exposing the test subjects to an active agent having the potential for diversion and abuse by humans. The evaluation can then be repeated using a formulation including such an active agent.
  • Additional testing can be conducted, for example, as discussed in the FDA document "Guidance for Industry Abuse-Deterrent Opioids - Evaluation and Labeling" (Januarty 2013, incorporated herein by reference). Such additional testing can include laboratory-based in vitro manipulation and extraction studies (e.g., to demonstrate impracticality of separating the active agent from the anti-diversive ingredient), pharmacokinetic studies, and clinical abuse potential studies (e.g., using a VAS to measure drug liking, good effects, bad effects and other drug abuse-related effects to show effectiveness in lowering the potential for abuse). It should be noted that the FDA document was addressed to formulations intended for use by humans (as opposed to preventing abuse by humans of a formulation intended for veterinary use).
  • Eudragit® RS 30D and Triacetin® are combined while passing through a 60 mesh screen, and mixed under low shear for approximately 5 minutes or until a uniform dispersion is observed.
  • the oxycodone HCI, lactose and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the previously obtained suspension is sprayed onto the powder in the fluid bed. After spraying, the granulation is passed through a #12 screen if necessary to reduce lumps.
  • the dry granulation is placed in a mixer, to which stearyl alcohol (previously melted at about 70°C) is added with mixing.
  • the resulting waxed granulation is transferred to a fluid bed granulator/dryer or to trays, and allowed to cool to room temperature or below, followed (if necessary) by passage through a #12 screen. Thereafter, the waxed granulation and Ipecac are placed in a mixer/blender and lubricated with the required amounts of talc and magnesium stearate for approximately 3 minutes, and then the granulate is compressed into 125 mg tablets on a suitable tableting machine.
  • Lactose USP (spray dried) 58.25 mg 46.6 % 58.25 g
  • Ipecac (powder) 1 .0 mg 0.8 % 1 .0 g
  • Example 1A the ipecac is substituted by a human effective amount of emetine, cephaeline, CCK8 and/or copper sulphate.
  • Example 1C the oxycodone hydrochloride is substituted by an therapeutically effective amount of buprenorphine, codeine, fentanyl, hydrocodone, meperidine, morphine sulfate, amphetamine/dextroamphetamine, dextroamphetamine, methylphenidate or dextromethorphan.
  • Example 1D In the formulation of Example 1A, the ipecac is formed into granules and coated to prevent release above pH 1.7, and then added to the waxed granulation when it is placed in the mixer/blender, lubricated with talc and magnesium stearate and compresssed into tablets.
  • Example 1A The formulation of Example 1A is prepared with the addition of a therapeutically effective amount of naltrexone.
  • Example 1A A quantity (30 units) of a veterinary formulation of Example 1A is sealed in one or more blister packs marked for twice-daily administration.
  • the blister packs are placed in a package labeled as follows:
  • test formulations Three batches of test formulations are prepared as described in Example 1 , containing 0 mg, 0.5 mg and 1.0 mg of ipecac, respectively. Each test formulation contains no oxycodone hydrochloride; reduction of oxycodone hydrochloride and ipecac % wt is adjusted for by increasing the amount of excipients.
  • 3B 24 Beagle dogs (12 sexually intact males and 12 sexually intact females) approximately 7 months old, weighing between 5 and 10 kg are randomized into three groups (of 4 males and females, each). To the subjects of each group are administered one tablet (containing 0 mg, 0.5 mg or 1.0 mg of ipecac, respectively). For one hour following administration, each subject is monitored for emetic events (vomiting or retching) and by observation of increased salivation, lip licking, frequent and/or exaggerated sallowing motions, lethargy, restlessness and/or panting. The results are quantified using a Visual Analog Scale (VAS). [058] 3C.
  • VAS Visual Analog Scale
  • Healthy adult human volunteers (12 males and 12 females) are randomized into three groups (of 4 males and females, each).
  • To the subjects of each group are administered one tablet (containing 0 mg, 0.5 mg or 1 .0 mg of ipecac, respectively).
  • each subject is monitored for emetic events (vomiting or retching).
  • the subjects each report the degree of nausea (if any) being experienced at ten-minute intervals during the hour.
  • the results are quantified using a Visual Analog Scale (VAS).
  • VAS Visual Analog Scale
  • test formulations Three batches of test formulations are prepared as described in Example 1 , containing 0 mg, 0.5 mg and 1.0 mg of ipecac, respectively. Each test formulation contains 10 mg oxycodone hydrochloride; reduction of oxycodone hydrochloride and ipecac % wt is adjusted for by increasing the amount of excipients.
  • [063] 4D The results from all three groups of dogs of Example 4B show the absence of emetic events.
  • the results from the human groups of Example 4C show no nausea or emetic events in the group receiving 0 mg of ipecac, but nausea and emetic events are shown in the groups receiving 0.5 mg and 1.0 mg of ipecac.
  • Formulations containing low doses of ipecac cause nausea in humans but not in dogs.
  • test formulations Three batches of test formulations are prepared as described in Example 1 , containing 0 mg, 0.5 mg and 1.0 mg of ipecac, respectively. Each test formulation contains 20 mg oxycodone hydrochloride; reduction of ipecac % wt is adjusted for by increasing the amount of excipients.

Abstract

La présente invention concerne des préparations et des formes galéniques vétérinaires résistantes à un usage détourné pour des principes actifs à risque d'usage détourné ou d'abus par des êtres humains.
PCT/US2014/035768 2013-04-29 2014-04-29 Formulation résistante à un usage détourné WO2014197137A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361816876P 2013-04-29 2013-04-29
US61/816,876 2013-04-29
US201361820292P 2013-05-07 2013-05-07
US61/820,292 2013-05-07

Publications (1)

Publication Number Publication Date
WO2014197137A1 true WO2014197137A1 (fr) 2014-12-11

Family

ID=52008481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/035768 WO2014197137A1 (fr) 2013-04-29 2014-04-29 Formulation résistante à un usage détourné

Country Status (1)

Country Link
WO (1) WO2014197137A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US20060018837A1 (en) * 2004-07-26 2006-01-26 Victory Pharma, Inc. Pharmaceutical compositions and methods for the prevention of drug misuse
WO2010081920A1 (fr) * 2009-01-15 2010-07-22 Raquel Miriam Rodriguez Valle Incorporation d'un émétique dans des médicaments en tant que système de sécurité face à d'éventuelles surdoses, en particulier dans des médicaments qui agissent sur le système nerveux central comme la benzodiazépine et ses dérivés, les barbituriques et des médicaments à usage pédiatrique
US20130017255A1 (en) * 2004-03-30 2013-01-17 Abreu Osvaldo Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US20130017255A1 (en) * 2004-03-30 2013-01-17 Abreu Osvaldo Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent
US20060018837A1 (en) * 2004-07-26 2006-01-26 Victory Pharma, Inc. Pharmaceutical compositions and methods for the prevention of drug misuse
WO2010081920A1 (fr) * 2009-01-15 2010-07-22 Raquel Miriam Rodriguez Valle Incorporation d'un émétique dans des médicaments en tant que système de sécurité face à d'éventuelles surdoses, en particulier dans des médicaments qui agissent sur le système nerveux central comme la benzodiazépine et ses dérivés, les barbituriques et des médicaments à usage pédiatrique

Similar Documents

Publication Publication Date Title
JP4997109B2 (ja) 用量比例的な定常状態ｃａｖｅおよび定常状態ａｕｃ、ならびに、用量比例よりも小さい単回投与ｃｍａｘを有するオピオイド投薬形態物
JP5844312B2 (ja) 事故的誤用および不法転用を防止するための耐破砕性錠剤
CA2640339C (fr) Formulations de dosage d'opioides infalsifiables
EP3045043B1 (fr) Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
US20160106680A1 (en) Abuse Deterrent Immediate Release Formulation
PT1615615E (pt) Produtos invioláveis para administração de opióides
HRP20110130T1 (hr) Oralni farmaceutski oblici doziranja otporni na manipuliranje koji sadrže opiodni analgetik
MX2013010987A (es) Formas de dosificacion farmaceutica de liberacion controlada.
US20160367550A1 (en) Naloxone Single Agent and Multilayer Tablets
US10624856B2 (en) Non-extractable oral solid dosage forms
WO2014197137A1 (fr) Formulation résistante à un usage détourné
EP3169315B1 (fr) Forme posologique remplie de liquide anti-abus à libération immédiate
US20170326134A1 (en) Abrasion-Resistant Opioid Formulations
AU2017208264B2 (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
US20160256451A1 (en) Dosage of naloxone
AU2011202866B2 (en) Tamper resistant dosage forms
US20160256453A1 (en) Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
WO2019152002A1 (fr) Formes posologiques solides orales non extractibles
US20160256452A1 (en) Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14808236

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14808236

Country of ref document: EP

Kind code of ref document: A1